A public company known for its work with cannabis health products for pets is ready to expand its presence in the Canadian medical market.

True Leaf Medicine International (CSE:MJ,OTCQB:TRLFF) provided its shareholders with an updated look into the development and completion schedule for a new cannabis cultivation facility.


The new facility’s phase 1 portion, currently under construction in Lumby, B.C. and slated for completion in fall 2018, will be capable of producing 15,000 kilograms of dried cannabis product per year at a price tag of approximately C$12 million, according to the leading executive of the company.

Darcy Bomford, CEO of True Leaf, told the Investing News Network (INN) this facility will be focused on the entry for the company in the legal medical market. As it moves forward alongside the policy, Bomford said he hopes for the company to extract its own CBD for pet products.

The facility, named True Leaf Campus, includes the first phase of a 16,000 square foot wing with hydroponic growth rooms and a 9,000 square feet section based on two floors with an initial grow area and laboratory services.

According to True Leaf’s statement, the company has obtained approval from Health Canada to build this growth facility and will undergo an inspection once it completes that construction. Bomford told INN the company will need to obtain licenses to grow and sell product in order to enter the market.

True Leaf to raise new capital later this year

In January the company raised C$14 million as part of an equity financing deal. Bomford told INN a solid portion of this capital helped the company secure the entire parcel of land where the new facility is.

He added the company will look to raise more money later this year in order to complete the construction process for this facility.

Bomford said the expectation is to raise close to C$50 million later this year and split the funds between its pets and medicinal divisions. Capital will also be allocated to acquisitions and general capital, he said.

Despite an initial upward trend for True Leaf’s common shares the day of the announcement (June 7), the company closed with a 7.27 percent loss and ending the day valued at C$0.51 per share.

On Monday’s (June 11) trading session the company finished with minimal change to its stock, staying at a price of C$0.52 per share.

Projection of the company’s plans according to its CEO

The timeline Bomford presented to INN shows it will take the nearly C$50 million market cap company nearly a year before it can start selling medical cannabis, due to licensing periods for inspection and approvals.

“That puts us in mid next year for selling product unless Health Canada speeds things up considerably,” Bomford said.

This isn’t the first time True Leaf has attempted to build out a licensed producer (LP) of cannabis in Canada. Back in 2013, the company made attempts to obtain a license for a facility in Vernon, B.C.

In 2014 Health Canada, the government agency tasked with providing licenses to grow cannabis, told the company ‘we’re not going to approve you at that location.’ Bomford went ahead and secured the Lumby site in April of 2014.

Expansion of pet cannabis market

True Leaf’s other division is based on the pet cannabis market with a supplement lineup of hemp-based oils, chewable items and other health products.

This year saw the entry of CannTrust Holdings (TSX:TRST) into the pet development area, as the LP signed on a partnership with Grey Wolf Animal Health, a private healthcare company working on a portfolio of products for pets.

Paul Trust, CEO of CannTrust said in a statement the LP would help develop “standardized cannabis products specifically designed for pets” alongside Grey Wolf in the future.

Canopy Growth (TSX:WEED), the largest publicly traded cannabis company, also recently announced efforts into the pet market, revealing it is developing cannabis extracts and formulations for cats, dogs and horses.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less